METTL3-IGF2BP3 m⁶A axis drives mutant huntingtin stability and neurodegeneration in Huntington’s disease

Technical Summary: METTL3-IGF2BP3 m⁶A Axis Drives Mutant Huntingtin Stability and Neurodegeneration in Huntington's Disease

Problem Statement
Huntington's disease (HD) is a fatal, inherited neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, resulting in the production of mutant huntingtin (mHTT) protein. While the genetic cause is established, the molecular mechanisms linking mHTT to selective neuronal vulnerability and degeneration remain incompletely understood. Emerging evidence suggests that post-transcriptional RNA regulation, specifically epitranscriptomic modifications like N⁶-methyladenosine (m⁶A), plays a role in HD pathogenesis. However, the specific contribution of m⁶A machinery dysregulation to mHTT stability, neuronal apoptosis, and neuroinflammation has not been fully defined.

Methodology
The study employed a multi-model approach to investigate the role of the m⁶A epitranscriptome in HD:

• Animal Models: Two distinct HD mouse models were utilized: the rapidly progressive transgenic R6/2 model and the full-length knock-in zQ175 model. Analyses were conducted on both the cortex and striatum, regions critical to HD pathology.
• Human Tissue: Postmortem brain tissues from HD patients (Grade II striatum and Grade IV cortex) and age-matched controls were examined to assess the conservation of findings in humans.
• Cellular Models: STHdh Q7 (wild-type) and Q111 (mutant) striatal cell lines were used to model HD-associated cellular stress under serum-deprived conditions at permissive (33°C) and non-permissive (37°C) temperatures.
• Experimental Interventions:
  • Pharmacological Inhibition: Cells were treated with STM2457, a selective small-molecule inhibitor of the m⁶A writer METTL3.
  • Genetic Knockdown: siRNA-mediated knockdown was used to deplete METTL3 and the m⁶A reader IGF2BP3.
• Analytical Techniques:
  • Gene Expression: Quantitative PCR (qPCR) was used to profile the expression of m⁶A writers (e.g., METTL3, METTL14), readers (e.g., IGF2BP3, YTHDFs), and erasers (e.g., ALKBH5).
  • Protein Analysis: Western blotting and immunoblotting assessed protein levels of m⁶A regulators, mHTT, and apoptotic markers (caspases).
  • Global Methylation: m⁶A dot-blot assays quantified global m⁶A RNA methylation levels.
  • Functional Assays: Cell viability (PrestoBlue), caspase activity (cleaved caspase-3/9), and inflammatory cytokine secretion (ELISA/qPCR) were measured.

Key Results

1. Dysregulation of m⁶A Machinery in HD Models: Transcriptomic and proteomic analyses revealed a widespread upregulation of m⁶A regulatory components in HD models.
   • In both R6/2 and zQ175 mice, the cortex and striatum showed significant upregulation of m⁶A writers (including METTL3, METTL14, and others) and readers (specifically IGF2BP3).
   • This transcriptional upregulation translated to increased protein levels of METTL3, METTL14, IGF2BP2, and IGF2BP3 in mouse brain regions.
   • Crucially, IGF2BP3 was identified as a consistently upregulated reader across all brain regions and both mouse models.
2. Conservation in Human HD Tissue: Similar to mouse models, human postmortem HD striatal (Grade II) and cortical (Grade IV) tissues exhibited significant upregulation of METTL3, IGF2BP2, and IGF2BP3 proteins, indicating that m⁶A dysregulation is an early and persistent feature of human HD pathology.
3. Elevated Global m⁶A Levels: Consistent with the upregulation of writers and readers, global m⁶A RNA methylation levels were significantly elevated in the cortex and striatum of HD mice and in Q111 cells compared to controls.
4. Functional Impact of METTL3 Inhibition:
   • Pharmacological inhibition of METTL3 using STM2457 in Q111 cells significantly reduced global m⁶A levels.
   • This reduction improved cell viability, suppressed the activation of executioner caspases (cleaved caspase-3 and -9), and attenuated the production of pro-inflammatory cytokines (IL-6, TNF-α, IFN-α/β, CXCL10, CCL5).
   • These protective effects were selective to mHTT-expressing (Q111) cells, with minimal impact on wild-type (Q7) cells.
5. The METTL3-m⁶A-IGF2BP3 Axis:
   • siRNA-mediated knockdown of METTL3 in Q111 cells reduced IGF2BP3 protein levels, decreased mHTT protein abundance, and attenuated caspase activation.
   • Knockdown of IGF2BP3 recapitulated these effects, reducing mHTT levels and caspase activation without altering METTL3 levels.
   • These findings delineate a mechanistic cascade where METTL3 deposits m⁶A on mHTT mRNA, promoting the binding of IGF2BP3. This interaction stabilizes the mHTT transcript and enhances its translation, leading to increased mHTT protein accumulation, subsequent caspase activation, and neuronal degeneration.

Significance and Claims
The paper establishes aberrant m⁶A RNA methylation as a conserved and active driver of mHTT accumulation, neuronal apoptosis, and neuroinflammation in Huntington's disease. The authors claim that:

• The m⁶A epitranscriptome is reprogrammed during HD pathogenesis, not merely as a consequence but as a driver of molecular and functional alterations.
• The METTL3-IGF2BP3 axis functions as a critical epitranscriptomic mechanism linking RNA modification directly to protein-level toxicity.
• Targeting this pathway (specifically via METTL3 inhibition or IGF2BP3 modulation) represents a promising therapeutic strategy to mitigate mHTT accumulation and neurodegeneration.
• The selective vulnerability of mHTT-expressing cells to m⁶A dysregulation suggests that epitranscriptomic therapies could potentially spare healthy neurons while targeting diseased ones.

The study concludes that the METTL3-IGF2BP3 pathway is a novel, modifiable therapeutic target for Huntington's disease, offering a new layer of understanding regarding the post-transcriptional regulation of mutant huntingtin stability.